FDA Approves AstraZeneca's IMFINZI Regimen for Bladder Cancer Patients
The FDA approved AstraZeneca's perioperative IMFINZI and enfortumab vedotin regimen for muscle-invasive bladder cancer patients who cannot receive cisplatin.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The US Food and Drug Administration approved AstraZeneca's regimen combining perioperative IMFINZI with neoadjuvant enfortumab vedotin-ejfv. The treatment is intended for adults with muscle-invasive bladder cancer who are ineligible for cisplatin or have declined it. TradingView reported the approval, citing AstraZeneca's press release distributed by BusinessWire.
In the Phase III VOLGA trial, the regimen cut the risk of event-free survival decline by 49% and the risk of death by 42% compared with the comparator. Grade 3 or 4 adverse events occurred in 64% of patients versus 44% in the comparator group. Applications in the EU, Japan and other markets are still under review, with no timing or outcomes specified.
why it matters
For AstraZeneca, this is the third IMFINZI indication in bladder cancer in two years. The US approval extends the drug into a patient group that previously had fewer options. However, the higher rate of severe side effects may weigh on prescribing decisions. Regulatory decisions in Europe and Japan will be the next key catalysts.
market impact
AstraZeneca shares: a new approved US treatment option supports expectations for the IMFINZI franchise
- AstraZeneca shares pressure up — the FDA approval adds a new US indication for IMFINZI
tags
instruments
sources
- AstraZeneca (AZN) Wins FDA Approval for IMFINZI Bladder Cancer Regimen — TradingView, 13 November 2026 at 23:39 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗